Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia

Luk, David C K; Hon, Kam Lun; Dizon, Maria Victoria; Leong, KinFon; Tay, Yong–Kwang; Koh, Mark Jean‐Aan; Chandran, Nisha Suyien; Wananukul, Siriwan; Chatproedprai, Susheera; Luger, Thomas A.

doi:10.1007/s13555-020-00467-8

Cited by 14 publications

(18 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…45,59,62 Cleansers with a nearphysiological pH of 5.5 and the addition of hydrating agents can provide both hygiene and moisturization (Box 2). 47,59,60,66 The past decade has seen considerable advances in understanding the role of moisturizers in AD management. 15,19,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]67 According to various guidelines, clinical pathways, and consensus papers, skincare using gentle cleansers and moisturizers are the cornerstone of all AD regimens regardless of ethnicity.…”

Section: Discussionmentioning

confidence: 99%

Insights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes

Alexis¹,

Woolery‐Lloyd²,

Andriessen³

et al. 2022

JDD

View full text Add to dashboard Cite

Background: Research on the role of race and ethnicity in the pathophysiology of atopic dermatitis (AD) is limited. Variations in the epidemiology, clinical presentation, and disease course in skin of color SOC AD patients have been reported. This manuscript seeks to offer insights into distinct features of AD in populations with (SOC) and provide recommendations on the role of skincare in treating AD amongst diverse populations. Methods: A literature review followed by panel discussions and an online review process explored best clinical practices in treating AD patients with SOC and providing expert guidance for skincare use, including gentle cleansers and moisturizers. Results: Some studies have identified differences in skin barrier properties in racial/ethnic groups affected by AD that may have implications for barrier function. Variations in the clinical presentation -including morphology, severity, and distribution -of AD in populations with SOC have been reported. Epidemiologic studies suggest a higher prevalence among self-identified Blacks/African Americans and greater health care utilization for AD among both Blacks/African Americans and Asian/Pacific Islanders. Pigmentary sequelae, including hyper-hypo-and depigmentation is a distinct feature of AD in patients with SOC that may contribute to the quality of life impact of the disorder. Xerosis may be more stigmatizing in SOC due to greater visibility of scale and dryness in the context of melanin-rich skin. Racial/ethnic variations in the prevalence of pruritus have also been reported, which may in turn have implications for AD in SOC. Treatment and maintenance of AD in patients with SOC should be proactive, effectively control inflammation longitudinally, include effective skin barrier protective strategies, and consider cultural practices. Conclusion:Robust comparative studies are needed to better understand racial/ethnic variations in AD. Further research will help to tailor patient education and foster individualized approaches to treatment, prevention, and adjunctive skin care across the diverse spectrum of patient populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Insights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes

Alexis¹,

Woolery‐Lloyd²,

Andriessen³

et al. 2022

JDD

View full text Add to dashboard Cite

show abstract

“…In most guidelines and consensus, a daily, frequent, regular application of moisturizers, which can help to enhance the skin barrier function, is recommended or required [ 23 , 36 , 39 , 43 , 56 , 57 ]. Asian countries also consider moisturizers as an important skincare method to provide better skin barrier function [ 23 , 36 , 43 , 57 , 58 ]. Emollients may be composed of humectants for promoting SC hydration and occlusives for reducing moisture evaporation.…”

Section: How Dexpanthenol Can Help In Admentioning

confidence: 99%

“…As first-line therapy for acute flares, emollients [ 65 ] and TCS [ 58 ] are recommended for treatment and remission of AD. For acutely inflamed flare lesions, the guidelines indicate that treatment with anti-inflammatory topicals, such as TCS or TCIs, is required first, rather than emollients alone [ 35 , 39 ].…”

Section: How Dexpanthenol Can Help In Admentioning

confidence: 99%

“…AD depicts various phenotypes and endotypes depending on age, chronicity, atopic status, or ethnicity [ 28 , 85 ]. For long-term maintenance therapy to maintain adequate skin hydration and prevent flares, moisturizers such as dexpanthenol ointment should be continuously used, at least twice daily, after the induction of remission by TCS [ 39 , 58 ].…”

Section: How Dexpanthenol Can Help In Admentioning

confidence: 99%

See 1 more Smart Citation

Use of Dexpanthenol for Atopic Dermatitis—Benefits and Recommendations Based on Current Evidence

Cho

Kim

Woo

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is an inflammatory skin disease of multiple phenotypes and endotypes, and is highly prevalent in children. Many people of all ages, including active adolescents, pregnant women, and the elderly, suffer from AD, experiencing chronicity, flares, and unexpected relapse. Dexpanthenol has multiple pharmacological effects and has been employed to treat various skin disorders such as AD. We aimed to summarize the up-to-date evidence relating to dexpanthenol and to provide a consensus on how to use dexpanthenol effectively for the treatment of AD. Methods: The evidence to date on the application and efficacy of dexpanthenol in AD was reviewed. The literature search focused on dexpanthenol use and the improvement of skin barrier function, the prevention of acute flares, and its topical corticosteroid (TCS) sparing effects. Evidence and recommendations for special groups such as pregnant women, and the effects of dexpanthenol and emollient plus in maintenance therapy, were also summarized. Results: Dexpanthenol is effective and well-tolerated for the treatment of AD. Dexpanthenol improves skin barrier function, reduces acute and frequent flares, has a significant TCS sparing effect, and enhances wound healing for skin lesions. Conclusion: This review article provides helpful advice for clinicians and patients on the proper maintenance treatment of AD. Dexpanthenol, as an active ingredient in ointments or emollients, is suitable for the treatment and maintenance of AD. This paper will guide dermatologists and clinicians to consider dexpanthenol as a treatment option for mild to moderate AD.

show abstract

“…Many guidelines and practical recommendations have been developed for the management of AD. 5,[39][40][41] Emollients and moisturizers are integral parts of AD management but are often not considered as topical medications. There have been a proliferation of emollients and moisturizers in recent years.…”

Section: Overview Of Therapies For Atopic Dermatitis Emollients and Moisturizersmentioning

confidence: 99%

Experimental Drugs with the Potential to Treat Atopic Eczema

Hon¹,

Chan²,

Leung

2021

JEP

Self Cite

View full text Add to dashboard Cite

Introduction: Eczema or atopic dermatitis (AD) is a chronically relapsing dermatosis characterized by pruritus and a significant impact on the quality of life. Methods: The authors undertook a structured search of peer-reviewed research articles from PubMed and Google Scholar. Recent and up-to-date studies relevant to the topic were included. Results: This report overviews current treatment and experimental drug for AD. Topical agents including topical phosphodiesterase E4 (PDE4) inhibitors such as crisaborole are efficacious in the treatment of AD with few side effects. Monoclonal antibodies such as dupilumab given subcutaneously are efficacious for more severe disease. Systemic treatment can ameliorate symptoms in severe and recalcitrant AD. New systemic treatment includes several traditional herbal formulations that have undergone clinical trials using modern research methodology to determine their efficacy and safety. AD is associated with many complicating psychosocial issues. Often suboptimal efficacy is due to unrealistic expectations and poor compliance making treatment difficult in spite of effective treatment and efforts in drug discovery. Randomized trials have shown that novel topical and subcutaneous medications are safe and efficacious. Regarding herbs, a methodology for the investigation of herbal medications is often flawed and scientific evidence is lacking. Experimental drugs include various biologics, PDE4 and JAK inhibitors in topical, oral, subcutaneous or intravenous forms are in various phases of trials. Conclusion: Many novel medications demonstrate efficacy for AD. Experimental drugs include various biologics, PDE4 and JAK inhibitors are in various phases of trials.

show abstract

Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia

Cited by 14 publications

References 89 publications

Insights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes

Insights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes

Use of Dexpanthenol for Atopic Dermatitis—Benefits and Recommendations Based on Current Evidence

Experimental Drugs with the Potential to Treat Atopic Eczema

Contact Info

Product

Resources

About